New Treatment Options Featured in NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines

JENKINTOWN, PA — The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, announces that the NCCN Non-Small Cell Lung Cancer Guideline has recently been updated to broaden the options for treatment of advanced disease. NCCN’s panel of oncology experts added pemetrexed (Alimta, Eli Lilly and Company) as an option for second-line therapy for lung cancer. The panel indicated that it has been shown to be equivalent to docetaxel (Taxotere, San...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news